Clinical trials: Cerebral Small Vessels Disease
Fabry Disease
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires…
- Trial name
- NCT04552691
- Testing
- Pegunigalsidase Alfa
- Where
- 11 sites in United States
- Sponsor
- Chiesi Farmaceutici S.p.A.
Fabry Disease
PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion
Pharmacokinetic/Pharmacodynamic Study of 2 agalsidase beta Formulations in Single Dose Administered to Healthy Volunteers as intravenous infusion, at a concentration of 1 mg/kg
- Trial name
- NCT05343715
- Testing
- Agalsidase beta from Biosidus 1 mg/kg, Fabrazyme (agalsidase beta) 1 mg/kg
- Where
- Argentina
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bio Sidus SA
Fabry Disease
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
This is the first human treatment with PRX-102, an enzyme being developed as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha galactosidase deficiency).
- Trial name
- NCT01678898
- Testing
- PRX-102
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 18 people
- Sponsor
- Protalix
ANCA-associated Vasculitis
Abatacept in ANCA Associated Vasculitis
The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blinded placebo controlled trial.
- Trial name
- ABAVAS (NCT00482066)
- Testing
- Abatacept (Orencia)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Fabry Disease
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
This was a multinational, open-label study to assess the efficacy and safety of AVR-RD-01 in approximately 15 male subjects, who were 16 years of age or older and postpubertal with a confirmed diagnosis of classic Fabry disease…
- Trial name
- NCT03454893
- Testing
- AVR-RD-01
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- AVROBIO
Stroke, Ischemic, Small Vessel Cerebrovascular Disease
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging.
- Conditions
- Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity
- Trial name
- Athena-cSVD (NCT06715007)
- Testing
- Clopidogrel, Aspirin, Cilostazol + Isosorbide Mononitrate
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Fabry Disease
Novel Diagnostic and Prognostic Predictors in Fabry Cardiomyopathy: Proof of Concept in a Rare Disease
In this work, we address the understanding of the signaling pathways involved in cardiac remodeling in human SCD through molecular imaging analysis with a fibrosis marker.
- Trial name
- FABRyCar (NCT07351136)
- Testing
- PET scan of 68Ga-FAPI
- Volunteers
- 20 people
- Sponsor
- Núcleo de Apoio à Investigação Clínica - FMUP
Cerebral Small Vessel Diseases
The Effect of Oral and Nasal Feeding on Cerebral Small Vessel Disease
Nasogastric tube feeding (NGT) has been widely used in cerebral small vessel disease (CSVD) patients with dysphagia but has a significant risk of complications.
- Trial name
- NCT06248892
- Testing
- Nasogastric Tube Feeding, Intermittent Oro-esophageal Tube Feeding, comprehensive rehabilitation therapy
- Where
- Thailand
- Volunteers
- 88 people
- Sponsor
- Zeng Changhao
Fabry Disease
China Post-marketing Surveillance (PMS) Study of Fabrazyme®
This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with Fabry Disease.
- Trial name
- NCT05054387
- Testing
- Agalsidase beta
- Where
- 6 sites in China
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Vasculitis, Wegener's Granulomatosis
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults.
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- RAVE (NCT00104299)
- Testing
- Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Fabry Disease, Chronic Kidney Diseases
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease
The overall objective of this study is to investigate Fabry-associated renal organ involvement by using a novel magnetic resonance imaging (MRI) approach, focusing on changes in renal oxygen levels by blood oxygenation-level…
- Trial name
- FORTIFY (NCT06325488)
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Caroline Michaela Kistorp
MELAS
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.
- Trial name
- NCT04475549
- Testing
- IW-6463 Tablets
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Tisento Therapeutics
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Cerebral Small Vessel Diseases, Dementia, Mixed
Dementia Risk Registry Across the Multidimensional Lifespan: A 10-Year Study
Age-related cerebral small-vessel disease (CSVD) is a major cause of dementia, predominantly affecting individuals over 60 years of age, with a prevalence exceeding 70% in the elderly population.
- Conditions
- Cerebral Small Vessel Diseases, Dementia, Mixed, Health Behavior, Health Behavior, Risky
- Trial name
- DREAM-10 (NCT06164262)
- Testing
- Individuals with CSVD
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Zhejiang Provincial People's Hospital
Brain Diseases, Aneurysm
PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM REGISTRATION TRIAL OF THE TUBRIDGE FOR THE TREATMENT OF WIDE-NECKED SMALL AND MEDIUM-SIZED INTRACRANIAL ANEURYSMS
A trial to evaluate the safety and efficacy of the Tubridge flow-diverter stent for the treatment of intracranial wide-necked, small to medium-sized aneurysms.
- Conditions
- Brain Diseases, Aneurysm, Intracranial Aneurysm, Cardiovascular Diseases
- Trial name
- NCT05829746
- Testing
- Tubridge
- Where
- China
- Volunteers
- 65 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Cerebral Small Vessel Diseases
Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）
Cerebral small vessel disease is a series of clinical, imaging and pathological syndromes caused by various etiologies affecting the arteries, capillaries, venules in the brain.
- Trial name
- NCT06061692
- Testing
- Tongxinluo Capsule
- Volunteers
- 1,052 people
- Sponsor
- Fudan University
Vascular Cognitive Impairment
Impact of Physical Activity in Vascular Cognitive Impairment ( AFIVASC )
Vascular cognitive impairment (VCI) is one of the most frequent causes of cognitive impairment associated with aging. So far, there is no approved treatment for VCI.
- Trial name
- AFIVASC (NCT03578614)
- Testing
- Physical Activity
- Where
- Portugal
- Volunteers
- 104 people
- Sponsor
- Instituto de Medicina Molecular João Lobo Antunes
Fabry Disease
Evaluation of the Effect of a Low-FODMAP Diet on Gastrointestinal Symptoms and Inflammatory Markers in Fabry Patients
The aim of this randomized controlled study is to evaluate the effects of a six-week low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet on gastrointestinal symptoms, inflammatory…
- Trial name
- FODMAPFABRY (NCT07888998)
- Testing
- Low-FODMAP Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Acibadem University
Extracranial Carotid Artery Aneurysm
ECAA Brain MRI: Seeking the Link Between Extracranial Carotid Artery Aneurysms and Small Vessel Disease
In order to understand which ECAA patients benefit from medical therapy, more should be known about the possible outcomes of this rare disease.
- Trial name
- NCT05828576
- Testing
- MRI
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- UMC Utrecht
Fabry Disease
Alpha-Galactosidase A Replacement Therapy for Fabry Disease
This study will determine the safety of the drug Replagal or treating patients with Fabry disease, an inherited metabolic disorder.
- Trial name
- NCT00048906
- Testing
- DRX005B
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)